The Journey Of Nemonoxacin

Name: The Journey Of Nemonoxacin
Price: 50.77 AUD
Availability: OutOfStock
ISBN: 9781971588339

Chi-Hsin Richard King

$55.95 $50.77

Hardback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We will update you on expected arrival time to us. If this delay is too long, please let us know within 2 business days and we can give you options regarding cancelling or adjusting your order. More details on cancelling your order can be found in our Terms of Trade.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Chi-Hsin Richard King
31 March 2026

Clinical & internal medicine; Pharmacology; Organic chemistry

Summary
Details

The narrative chronicled in the book offers a comprehensive account of the journey of Nemonoxacin, tracing its evolution from its inception as a novel chemical entity to its successful commercial launch in various formulations. Nemonoxacin debuted in the pharmaceutical market as Taigexyn(R) Capsule, a 250 mg oral dosage form, approved in Taiwan in 2014 and subsequently in China in 2016. It further expanded its presence with the introduction of Taigexyn(R) Intravenous Injection, a 500 mg/250 mL preparation for parenteral administration, which gained approval in Taiwan (2020), China (2021), and Russia (2022).

The international reach of Taigexyn(R) has been significantly enhanced through a strategic licensing agreement with R-Pharm, which opened doors to the markets in Russia, Turkey, and all the member countries of the Commonwealth of Independent States (CIS). Moreover, partnerships have secured exclusive distribution and sales rights for Nemonoxacin in key global markets. These include an agreement with Productos Científicos S.A. de C.V. for the Latin American region, with Luminarie for English-speaking countries such as Canada, New Zealand, and Australia, and with Y.S.P. Industries (M) Sdn. Bhd. for Malaysia and Singapore.

Nemonoxacin's designation as a ""Qualified Infectious Disease Product (QIDP)"" and its receipt of ""Fast Track Status"" from the US FDA for the treatment of Community-Acquired Bacterial Pneumonia (CABP) and Acute Bacterial Skin and Skin Structure Infections (ABSSSI) underscores its therapeutic potential and significance. These designations have paved the way for Phase III clinical development in the United States, focusing on these indications with the backing of substantial financial support from prominent pharmaceutical partners. This progression marks a pivotal phase in Nemonoxacin's journey towards addressing unmet medical needs and improving patient care on a global scale.

By: Chi-Hsin Richard King
Imprint: Chi-Hsin Richard King
Dimensions: Height: 229mm, Width: 152mm, Spine: 13mm
Weight: 431g
ISBN: 9781971588339
ISBN 10: 1971588334
Pages: 196
Publication Date: 31 March 2026
Audience: General/trade , ELT Advanced
Format: Hardback
Publisher's Status: Active